ABSTRACT
INTRODUCTION Overview With human lifespan rising in developed nations, age-related macular degeneration (AMD) continues to grow as the leading cause of central vision loss and legal blindness in elderly adults (1,2). Current medical treatment with vitamin and mineral supplementation lowers the risk of progression to neovascular advanced AMD, and it may potentially delay the onset of non-neovascular advanced AMD characterized by central geographic atrophy (GA) (3). Medical treatments for neovascular AMD include thermal laser photocoagulation, photodynamic therapy (PDT) with intravenous verteporfi n, and intravitreal injection of antibodies targeting vascular endothelial growth factor (VEGF).
